Loading chat...
NY A05354
Bill
Status
2/13/2025
Primary Sponsor
Phillip Steck
Click for details
AI Summary
-
Requires health insurance policies that cover prescription drugs to include coverage for at least one opioid antagonist and device (such as naloxone) without prior authorization or premedical review
-
Prohibits insurers from imposing deductibles, co-insurance, co-payments, or any other cost-sharing requirements for opioid antagonist coverage
-
Defines "opioid antagonist and device" as FDA-approved drugs that negate or neutralize the pharmacological effects of opioids, limited to medications approved by the Department of Health
-
Extends coverage to opioid antagonists prescribed via standing order or collaborative practice agreement for use on patients other than the insured person
-
Applies to individual, group, and blanket health insurance policies issued, renewed, or amended on or after January 1, 2026
Legislative Description
Requires health insurers to provide coverage without cost-sharing for opioid antagonists and devices; provides that no prior authorization of premedical review for coverage of such opioid antagonist is required.
Last Action
referred to insurance
1/7/2026